Lauren A Marcath1, Kelley M Kidwell2,3, Kiran Vangipuram4, Christina L Gersch2, James M Rae2, Monika L Burness2,5, Jennifer J Griggs2,5, Catherine Van Poznak2,5, Daniel F Hayes2,5, Ellen M Lavoie Smith6, N Lynn Henry7, Andreas S Beutler8,9, Daniel L Hertz4. 1. Department of Pharmacotherapy, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, WA, USA. 2. University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. 3. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA. 4. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA. 5. Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA. 6. Department of Health Behavior and Biological Sciences, University of Michigan School of Nursing, Ann Arbor, MI, USA. 7. Department of Internal Medicine, Division of Oncology, University of Utah School of Medicine, Salt Lake City, UT, USA. 8. Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA. 9. Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Abstract
AIMS: Chemotherapy-induced peripheral neuropathy (PN) is a treatment limiting toxicity of paclitaxel. We evaluated if EPHA genetic variation (EPHA4, EPHA5, EPHA6, and EPHA8) is associated with PN sensitivity by accounting for variability in systemic paclitaxel exposure (time above threshold). METHODS: Germline DNA from 60 patients with breast cancer was sequenced. PN was measured using the 8-item sensory subscale (CIPN8) of the patient-reported CIPN20. Associations for 3 genetic models were tested by incorporating genetics into previously published PN prediction models integrating measured paclitaxel exposure and cumulative treatment. Significant associations were then tested for association with PN-related treatment disruption. RESULTS: EPHA5 rs7349683 (minor allele frequency = 0.32) was associated with increased PN sensitivity (β-coefficient = 0.39, 95% confidence interval 0.11-0.67, p = 0.007). Setting a maximum tolerable threshold of CIPN8 = 30, optimal paclitaxel exposure target is shorter for rs7349683 homozygous (11.6 h) than heterozygous (12.6 h) or wild-type (13.6 h) patients. Total number of missense variants (median = 0, range 0-2) was associated with decreased PN sensitivity (β-coefficient: -0.42, 95% confidence interval -0.72 to -0.12, P = .006). No association with treatment disruption was detected for the total number of missense variants or rs7349683. CONCLUSION: Isolating toxicity sensitivity by accounting for exposure is a novel approach, and rs7349683 represents a promising marker for PN sensitivity that may be used to individualize paclitaxel treatment.
AIMS: Chemotherapy-induced peripheral neuropathy (PN) is a treatment limiting toxicity of paclitaxel. We evaluated if EPHA genetic variation (EPHA4, EPHA5, EPHA6, and EPHA8) is associated with PN sensitivity by accounting for variability in systemic paclitaxel exposure (time above threshold). METHODS: Germline DNA from 60 patients with breast cancer was sequenced. PN was measured using the 8-item sensory subscale (CIPN8) of the patient-reported CIPN20. Associations for 3 genetic models were tested by incorporating genetics into previously published PN prediction models integrating measured paclitaxel exposure and cumulative treatment. Significant associations were then tested for association with PN-related treatment disruption. RESULTS:EPHA5rs7349683 (minor allele frequency = 0.32) was associated with increased PN sensitivity (β-coefficient = 0.39, 95% confidence interval 0.11-0.67, p = 0.007). Setting a maximum tolerable threshold of CIPN8 = 30, optimal paclitaxel exposure target is shorter for rs7349683 homozygous (11.6 h) than heterozygous (12.6 h) or wild-type (13.6 h) patients. Total number of missense variants (median = 0, range 0-2) was associated with decreased PN sensitivity (β-coefficient: -0.42, 95% confidence interval -0.72 to -0.12, P = .006). No association with treatment disruption was detected for the total number of missense variants or rs7349683. CONCLUSION: Isolating toxicity sensitivity by accounting for exposure is a novel approach, and rs7349683 represents a promising marker for PN sensitivity that may be used to individualize paclitaxel treatment.
Authors: George T Budd; William E Barlow; Halle C F Moore; Timothy J Hobday; James A Stewart; Claudine Isaacs; Muhammad Salim; Jonathan K Cho; Kristine J Rinn; Kathy S Albain; Helen K Chew; Gary V Burton; Timothy D Moore; Gordan Srkalovic; Bradley A McGregor; Lawrence E Flaherty; Robert B Livingston; Danika L Lew; Julie R Gralow; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2014-11-24 Impact factor: 44.544
Authors: Andreas S Beutler; Amit A Kulkarni; Rahul Kanwar; Christopher J Klein; Terry M Therneau; Rui Qin; Michaela S Banck; Ganesh K Boora; Kathryn J Ruddy; Yanhong Wu; Regenia L Smalley; Julie M Cunningham; Nguyet Anh Le-Lindqwister; Peter Beyerlein; Gary P Schroth; Anthony J Windebank; Stephan Züchner; Charles L Loprinzi Journal: Ann Neurol Date: 2014-09-17 Impact factor: 10.422
Authors: Anne-Joy M de Graan; Laure Elens; Jason A Sprowl; Alex Sparreboom; Lena E Friberg; Bronno van der Holt; Pleun J de Raaf; Peter de Bruijn; Frederike K Engels; Ferry A L M Eskens; Erik A C Wiemer; Jaap Verweij; Ron H J Mathijssen; Ron H N van Schaik Journal: Clin Cancer Res Date: 2013-05-02 Impact factor: 12.531
Authors: Lu Zhang; Qingzhao Yu; Xiao-Cheng Wu; Mei-Chin Hsieh; Michelle Loch; Vivien W Chen; Elizabeth Fontham; Tekeda Ferguson Journal: Breast Cancer Res Treat Date: 2018-01-24 Impact factor: 4.872
Authors: Joseph A Sparano; Fengmin Zhao; Silvana Martino; Jennifer A Ligibel; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson Journal: J Clin Oncol Date: 2015-06-15 Impact factor: 44.544
Authors: Martin Kircher; Daniela M Witten; Preti Jain; Brian J O'Roak; Gregory M Cooper; Jay Shendure Journal: Nat Genet Date: 2014-02-02 Impact factor: 38.330
Authors: Bryan P Schneider; Dongbing Lai; Fei Shen; Guanglong Jiang; Milan Radovich; Lang Li; Laura Gardner; Kathy D Miller; Anne O'Neill; Joseph A Sparano; Gloria Xue; Tatiana Foroud; George W Sledge Journal: Oncotarget Date: 2016-12-13
Authors: Yongzhen Chen; Fang Fang; Kelley M Kidwell; Kiran Vangipuram; Lauren A Marcath; Christina L Gersch; James M Rae; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry; Andreas S Beutler; Daniel L Hertz Journal: Pharmacogenomics Date: 2020-07-23 Impact factor: 2.533
Authors: Alberto Guijosa; Ana Freyria; Jose Rodrigo Espinosa-Fernandez; Francisco J Estrada-Mena; Ana Sofía Armenta-Quiroga; Maria Fernanda Ortega-Treviño; Rodrigo Catalán; Bani Antonio-Aguirre; Cynthia Villarreal-Garza; Andric C Perez-Ortiz Journal: Clin Transl Sci Date: 2022-08-17 Impact factor: 4.438
Authors: Lauren A Marcath; Kelley M Kidwell; Kiran Vangipuram; Christina L Gersch; James M Rae; Monika L Burness; Jennifer J Griggs; Catherine Van Poznak; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry; Andreas S Beutler; Daniel L Hertz Journal: Br J Clin Pharmacol Date: 2020-02-04 Impact factor: 4.335